• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of and Evidence.索磷布韦治疗戊型肝炎病毒感染：一项综述及证据
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003. Epub 2022 Feb 22.
2
A small animal model of chronic hepatitis E infection using immunocompromised rats.一种使用免疫受损大鼠建立的戊型肝炎慢性感染小动物模型。
JHEP Rep. 2022 Aug 10;4(10):100546. doi: 10.1016/j.jhepr.2022.100546. eCollection 2022 Oct.
3
Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection.来迪派韦/索磷布韦与利巴韦林联合治疗对利巴韦林耐药的持续性戊型肝炎病毒感染
IDCases. 2023 Mar 6;32:e01741. doi: 10.1016/j.idcr.2023.e01741. eCollection 2023.
4
ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.ISG15在戊型肝炎病毒复制过程中调节I型干扰素信号传导和抗病毒反应。
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.00621-17. Print 2017 Oct 1.
5
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.成功治疗 HBV、HCV 和 HEV，使用替诺福韦、索磷布韦、达拉他韦和利巴韦林治疗 12 周：一例报告。
J Infect Public Health. 2020 Jan;13(1):149-150. doi: 10.1016/j.jiph.2019.06.004. Epub 2019 Jun 21.
6
Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.索磷布韦联合利巴韦林治疗肝硬化肝移植受者慢性戊型肝炎：病例报告。
BMC Gastroenterol. 2019 May 24;19(1):76. doi: 10.1186/s12876-019-0995-z.
7
Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.一名心脏移植患者的慢性戊型肝炎：索磷布韦和利巴韦林治疗方案效果不完全理想。
Antivir Ther. 2018;23(5):463-465. doi: 10.3851/IMP3227.
8
Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.印度大多数丙型肝炎病毒感染患者接受基于干扰素的抗病毒治疗时就诊较晚：一项对北印度一家三级医疗中心777例患者的流行病学研究。
J Clin Exp Hepatol. 2015 Jun;5(2):134-41. doi: 10.1016/j.jceh.2015.05.001. Epub 2015 May 21.
9
Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.儿童肾移植受者中戊型肝炎病毒感染的流行率、发病率和治疗。
Pediatr Nephrol. 2018 Jul;33(7):1215-1225. doi: 10.1007/s00467-018-3905-7. Epub 2018 Mar 2.
10
Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.MicroRNA-122 对戊型肝炎病毒复制的正调控作用。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.01999-17. Print 2018 Jun 1.

引用本文的文献

1
Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)-Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection?采用戊型肝炎病毒（HEV）特异性T细胞的过继性免疫疗法能否满足难治性慢性戊型肝炎感染中未被满足的需求？
Open Forum Infect Dis. 2025 May 27;12(5):ofaf231. doi: 10.1093/ofid/ofaf231. eCollection 2025 May.
2
Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.三种不同的戊型肝炎病毒报告系统及其作为药物筛选平台的应用。
Viruses. 2023 Sep 23;15(10):1989. doi: 10.3390/v15101989.
3
Puzzles for Hepatitis E Virus.戊型肝炎病毒之谜。
Adv Exp Med Biol. 2023;1417:247-256. doi: 10.1007/978-981-99-1304-6_17.

本文引用的文献

1
Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study.索磷布韦单药治疗无法清除慢性戊型肝炎患者的戊型肝炎病毒RNA——HepNet SofE试点研究
J Hepatol. 2020 Sep;73(3):696-699. doi: 10.1016/j.jhep.2020.05.020. Epub 2020 Jul 2.
2
Hepatitis E: an expanding epidemic with a range of complications.戊型肝炎：一种不断扩大的流行疾病，有多种并发症。
Clin Microbiol Infect. 2020 Jul;26(7):828-832. doi: 10.1016/j.cmi.2020.03.039. Epub 2020 Apr 3.
3
Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients.戊型肝炎病毒在异基因造血干细胞移植受者中是一种不常见但可能严重的感染。
Bone Marrow Transplant. 2020 Jul;55(7):1255-1263. doi: 10.1038/s41409-020-0823-7. Epub 2020 Feb 18.
4
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.器官移植后戊型肝炎病毒感染的利巴韦林治疗：一项大型的欧洲回顾性多中心研究。
Clin Infect Dis. 2020 Aug 22;71(5):1204-1211. doi: 10.1093/cid/ciz953.
5
Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response.在实体器官移植受者中，索磷布韦联合利巴韦林治疗慢性戊型肝炎病毒感染未产生持续病毒学应答。
Open Forum Infect Dis. 2019 Aug 1;6(8). doi: 10.1093/ofid/ofz346.
6
Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.抗戊型肝炎病毒（HEV）的抗病毒候选药物及其组合在体外抑制 HEV 的生长。
Antiviral Res. 2019 Oct;170:104570. doi: 10.1016/j.antiviral.2019.104570. Epub 2019 Jul 27.
7
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.成功治疗 HBV、HCV 和 HEV，使用替诺福韦、索磷布韦、达拉他韦和利巴韦林治疗 12 周：一例报告。
J Infect Public Health. 2020 Jan;13(1):149-150. doi: 10.1016/j.jiph.2019.06.004. Epub 2019 Jun 21.
8
Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.索磷布韦联合利巴韦林治疗肝硬化肝移植受者慢性戊型肝炎：病例报告。
BMC Gastroenterol. 2019 May 24;19(1):76. doi: 10.1186/s12876-019-0995-z.
9
Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.索磷布韦与利巴韦林联合治疗未能清除一名多脏器移植患者的慢性戊型肝炎感染。
J Hepatol. 2019 Jul;71(1):225-227. doi: 10.1016/j.jhep.2019.03.029. Epub 2019 Apr 23.
10
Antiviral Candidates for Treating Hepatitis E Virus Infection.抗戊型肝炎病毒药物治疗的候选药物。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00003-19. Print 2019 Jun.

索磷布韦治疗戊型肝炎病毒感染：一项综述及证据

Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of and Evidence.

作者信息

Lampejo Temi

机构信息

Infection Sciences, King's College Hospital, London, United Kingdom.

出版信息

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003. Epub 2022 Feb 22.

DOI:10.1016/j.jceh.2022.02.003
PMID:35814503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9257862/
Abstract

Chronic hepatitis E virus (HEV) infection, which occurs almost exclusively in immunocompromised patients, if untreated may progress to cirrhosis and possibly hepatocellular carcinoma. The reduction of immunosuppression and/or administration of ribavirin is frequently curative but there remain many immunocompromised individuals whose HEV infection is refractory to these therapeutic strategies. Moreover, the haematological toxicity of ribavirin limits its use. Pegylated interferon has demonstrated success in a small number of patients with chronic HEV infection; however, the potentially increased risk of graft rejection associated with its use renders it unsuitable for many transplant recipients. Alternative therapeutic strategies are therefore required. This article reviews the and literature to date of the antiviral agent sofosbuvir (well established in the treatment of hepatitis C) in the treatment of HEV infection.

摘要

慢性戊型肝炎病毒（HEV）感染几乎仅发生于免疫功能低下的患者，若不治疗可能进展为肝硬化，并有可能发展为肝细胞癌。减少免疫抑制和/或使用利巴韦林通常可治愈疾病，但仍有许多免疫功能低下的个体，其HEV感染对这些治疗策略无效。此外，利巴韦林的血液学毒性限制了其使用。聚乙二醇干扰素已在少数慢性HEV感染患者中显示出疗效；然而，其使用可能增加移植排斥反应的风险，使其不适用于许多移植受者。因此，需要其他治疗策略。本文综述了抗病毒药物索磷布韦（在丙型肝炎治疗中已得到充分确立）治疗HEV感染的现有文献。